Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Anne Wojcicki, co-founder of 23andMe, is urging a U.S. judge to reopen the genetic testing company’s bankruptcy auction, claiming support from a Fortune 500 company with a market cap exceeding $400 billion. While the backer remains unnamed in court filings, Wojcicki argues the auction process unfairly excluded her nonprofit group, TTAM Research Institute.
23andMe filed for Chapter 11 bankruptcy in April 2025 following declining demand and a 2023 data breach affecting millions of users' sensitive genetic data. In May, biotech firm Regeneron Pharmaceuticals (NASDAQ: REGN) won the auction with a $256 million bid, surpassing TTAM and Wojcicki’s $146 million offer.
In a new filing dated May 31, Wojcicki alleges 23andMe’s advisers unfairly capped TTAM’s bid at $250 million over doubts about its financial capacity. She insists TTAM was prepared to bid over $280 million but was blocked before submitting the higher offer. Wojcicki contends the auction was prematurely closed to favor Regeneron.
23andMe’s debtors, however, maintain that the process was overseen by a special committee of independent directors and conducted fairly. According to recent court documents, the company now seeks approval to allow both Regeneron and Wojcicki to submit final proposals by June 12.
If Wojcicki’s bid is chosen, 23andMe is requesting court approval to pay Regeneron a $10 million breakup fee. None of the involved parties—Regeneron, TTAM, or 23andMe’s legal teams—have commented publicly on the latest developments.
This high-stakes legal dispute underscores the competitive value of 23andMe’s genetic data business amid shifting market dynamics and privacy concerns. The case could also set a precedent for bankruptcy auctions involving nonprofit bidders.
